Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00126620
Other study ID # PMH-PHL-042
Secondary ID CDR0000437855NCI
Status Completed
Phase Phase 1
First received August 2, 2005
Last updated July 22, 2015
Start date September 2005

Study information

Verified date July 2015
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib and erlotinib in treating patients with metastatic or unresectable solid tumors.


Description:

OBJECTIVES:

Primary

- Determine the maximum tolerated dose and recommended phase II dose of sorafenib and erlotinib in patients with metastatic or unresectable solid tumors.

Secondary

- Determine the optimal biologically effective dose of this regimen that will lead to hypophosphorylation of epidermal growth factor receptor (EGFR), ERK, Akt, and vascular endothelial growth factor receptor (VEGFR), and inhibition of angiogenesis and apoptosis with tolerable toxicity in these patients.

- Correlate the pharmacokinetic profiles of this regimen with toxicity and biological activity in these patients.

- Determine, preliminarily, the antitumor activity of this regimen in these patients.

- Correlate phosphorylation status of EGFR, ERK, Akt, and VEGFR with antitumor activity of this regimen in these patients.

OUTLINE: This is a multicenter, open label, non-randomized, dose-escalation study.

Patients receive oral sorafenib alone once or twice daily on days -6 to 0*. Patients then receive oral sorafenib once or twice daily and oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

NOTE: *Not considered part of course 1; considered a "run-in" period only.

Cohorts of 3-6 patients receive escalating doses of sorafenib and erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 10 patients are treated at the MTD.

After completion of study treatment, patients are followed at 4 weeks and then at least annually thereafter.

PROJECTED ACCRUAL: A total of 16-28 patients will be accrued for this study within 5-14 months.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed solid tumor

- Metastatic or unresectable disease

- Standard curative or palliative measures do not exist OR are no longer effective

- Measurable disease by radiography (for patients treated at the maximum tolerated dose [MTD] only)

- Tumor accessible for serial biopsies (for patients treated at the MTD only)

- No known brain metastases

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- ECOG 0-2 OR

- Karnofsky 60-100%

Life expectancy

- More than 12 weeks

Hematopoietic

- WBC = 3,000/mm^3

- Absolute neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

- No bleeding diathesis or coagulopathy

Hepatic

- Bilirubin normal

- AST and ALT = 2.5 times ULN

- PT INR = 1.5 unless on full-dose warfarin

Renal

- Creatinine normal OR

- Creatinine clearance = 60 mL/min

Cardiovascular

- No uncontrolled hypertension (i.e., systolic blood pressure [BP] > 140 mm Hg or diastolic BP > 90 mm Hg despite medication)

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

Ophthalmic

- No abnormalities of the cornea, including any of the following:

- Dry eye syndrome

- Sjögren's syndrome

- Congenital abnormalities (e.g., Fuch's dystrophy)

- Abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)

- Abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test)

Gastrointestinal

- No active peptic ulcer disease that would impair the ability to swallow pills

- No gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Willing to undergo serial biopsies, positron emission tomography, and CT scanning (for patients treated at the MTD only)

- No ongoing or active infection

- No significant traumatic injury within the past 3 weeks

- No history of allergic reaction to drugs of similar chemical or biological composition to study drugs

- No psychiatric illness or social situation that would preclude study compliance

- No other condition that would impair the ability to swallow pills

- No other uncontrolled illness

PRIOR CONCURRENT THERAPY:

Biologic therapy

- No concurrent prophylactic hematopoietic colony-stimulating factors

Chemotherapy

- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered

Endocrine therapy

- Not specified

Radiotherapy

- More than 4 weeks since prior radiotherapy (except for low dose, non-myelosuppressive radiotherapy) and recovered

Surgery

- More than 3 weeks since prior major surgery

- No prior surgical procedure affecting absorption

Other

- No prior sorafenib or erlotinib

- No other prior agents targeting Raf, vascular endothelial growth factor (VEGF), VEGF receptor, or epidermal growth factor receptor

- No other concurrent investigational agents

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)

- No concurrent CYP3A4 inducers (e.g., rifampin or Hypericum perforatum [St. John's wort])

- No other concurrent anticancer therapy

- Concurrent prophylactic anticoagulation therapy (e.g., low-dose warfarin) allowed provided PT INR < 1.1 times upper limit of normal (ULN)

- Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 allowed provided both of the following criteria are met:

- Patient has an in range INR (between 2-3) while on a stable-dose of oral anti-coagulant OR a stable-dose of low molecular weight heparin

- No active bleeding OR pathological condition that would confer a high risk of bleeding (e.g., tumor involving a major vessel or known varices)

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Unspecified Adult Solid Tumor, Protocol Specific

Intervention

Drug:
erlotinib hydrochloride

sorafenib tosylate


Locations

Country Name City State
Canada Margaret and Charles Juravinski Cancer Centre Hamilton Ontario
Canada Princess Margaret Hospital Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
University Health Network, Toronto National Cancer Institute (NCI)

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Duran I, Hotté SJ, Hirte H, Chen EX, MacLean M, Turner S, Duan L, Pond GR, Lathia C, Walsh S, Wright JJ, Dancey J, Siu LL. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2007 Aug 15;1 — View Citation

Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, MacLean M, Nayyar R, Tusche MW, Metser U, Wright JJ, Mak TW, Siu LL. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose and recommended phase II dose 28 days Yes
Secondary Pharmacodynamic outcomes Pre study and cycle 1 No
Secondary Pharmacokinetic outcomes Pre-study, cycle 1 and cycle 2 No
Secondary Antitumor activity Every 8 wks No
Secondary Correlation of EGFR, AKT, ERK and VEGFR with antitumor activity If responses or prolonged stable disease are observed No
Secondary EGFR activating mutations, gene amplification status, EGFR intron 1 polymorphism if responses or prolonged disease stabilization are seen If responses or prolonged stable disease are observed No
See also
  Status Clinical Trial Phase
Completed NCT01828775 - Palliative Care Intervention in Improving Quality of Life, Psychological Distress, and Communication in Patients With Solid Tumors Receiving Treatment N/A
Terminated NCT01642342 - Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Phase 1
Completed NCT00002950 - Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer Phase 1/Phase 2
Completed NCT01705548 - Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis N/A
Completed NCT02146222 - VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors Phase 1
Terminated NCT01602627 - Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies Phase 1
Completed NCT01191216 - 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors Phase 1
Recruiting NCT00992303 - Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Recruiting NCT01137825 - Registry of Older Patients With Cancer
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00949949 - Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy Phase 1
Completed NCT00924651 - Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy Phase 3
Withdrawn NCT00937417 - S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT00710632 - Screening to Predict Weight Loss in Patients With Cancer N/A
Completed NCT00573690 - Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors Phase 1
Completed NCT00544596 - R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer Phase 1
Active, not recruiting NCT00436735 - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase 1
Completed NCT00352443 - S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Phase 1
Completed NCT00255658 - Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors Phase 1
Completed NCT00121277 - Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors Phase 1